Journal of Neuroimmune Pharmacology

, Volume 8, Issue 1, pp 37–41

Resolvin E1 Inhibits Neuropathic Pain and Spinal Cord Microglial Activation Following Peripheral Nerve Injury

BRIEF REPORT

DOI: 10.1007/s11481-012-9394-8

Cite this article as:
Xu, ZZ., Berta, T. & Ji, RR. J Neuroimmune Pharmacol (2013) 8: 37. doi:10.1007/s11481-012-9394-8

Abstract

Accumulating evidence indicates that activation of spinal cord microglia plays an important role in the genesis of neuropathic pain. Resolvin E1 (E1) is derived from omega-3 polyunsaturated fatty acid and exhibits potent anti-inflammatory, pro-resolution, and anti-nociceptive effects. We further examined whether RvE1 could reduce neuropathic pain and modulate spinal cord microglial activation. Intrathecal pre-treatment of RvE1 (100 ng) daily for 3 days partially prevented the development of nerve injury-induced mechanical allodynia and up-regulation of IBA-1 (microglial marker) and TNF-α in the spinal cord dorsal horn. Furthermore, intrathecal post-treatment of RvE1 (100 ng), 3 weeks after nerve injury, transiently reduced mechanical allodynia and heat hyperalgesia. Finally, RvE1 blocked lipopolisaccharide-induced microgliosis and TNF-α release in primary micoglial cultures. Our data suggest that RvE1 may attenuate neuropathic pain via inhibiting microglial signaling. Targeting the anti-inflammatory and pro-resolution lipid mediators may offer new options for preventing and treating neuropathic pain.

Keywords

Eicosapentaenoic acid (EPA) Tumor necrosis factor-alpha (TNF-α) Lipopolisacride (LPS) Nerve injury Omega-3 poly unsaturated fatty acids Spinal cord 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Sensory Plasticity Laboratory, Pain Research Center, Department of AnesthesiologyBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Sensory Plasticity Laboratory, Department of AnesthesiologyDuke University Medical CenterDurhamUSA

Personalised recommendations